Clinical Trials Logo

Clinical Trial Summary

The purpose of this stage of study is to establish discriminant among healthy tissue, benign and malignant thyroid and breast tumors by fourier transform infrared spectrometry variables.


Clinical Trial Description

Recently,the methods to the diagnosis of tumors include palpation,X-ray,ultrasound,CT and MRI.The doctors could not get conclusion without a existing mass.The FNB is very popular nowadays in western countries,but it has been reported that about one-third malignant cases have been neglected by FNB,for the tissue isn't enough through the needle.There also have been reports about the increased auxilliary lymphnode metastases for breast cancer because of FNB.Although the Mammotome has been used widely,it is still traumatic.

Process of malignant transformation of tissues and cells, first proteins, lipids, carbohydrates and nucleic acids constitute the main substance of tissue and cell structure, conformation, and the number of occurrence of significant changes in subsequent histological changes. Fourier transform infrared spectroscopy is the major molecular bond coupling between the atoms vibrational spectra and molecular rotational spectra.

In this study, consists of three phases:

Stage one:

Continuous enrollment requires inpatient surgery 300 cases of thyroid cancer patients and breast cancer patients, 200 cases of preoperative determination of tumor on the surface infrared spectroscopy, infrared spectroscopy of the anterior tumor tissue and lymph node surgery, measured in vivo; at the same time into the group of 50 patients healthy people, the determination of surface infrared spectroscopy of the thyroid and breast area. Paraffin pathological findings as the gold standard, the thyroid and breast cancer patients were divided into the benign group and malignant group, relatively healthy and good, the distribution of differences of the surface infrared spectrum of malignant group, while relatively good in the malignant group IR spectra of the distribution of differences.

Phase II:

Were enrolled, infrared spectroscopy and pathological specimens were collected at different stages. Paraffin pathological findings as the gold standard, were established two tumor surface, the infrared spectra of the fresh in vitro and in vivo for tumor benign or malignant diagnosis discrimination system.

Phase III:

Into the infrared spectra collected data on behalf of the above-mentioned discrimination system to verify its sensitivity, specificity and accuracy; both paraffin pathological findings as the gold standard to compare the infrared spectral discrimination systems and intraoperative frozen section pathology for the diagnosis of benign and malignant tumors correctly rate differences, to explore the clinical value of infrared spectroscopy discrimination system. ;


Study Design

Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT01668238
Study type Observational
Source Peking University
Contact Zhi XU, PHD MD
Phone 86-10-82267331
Email xuzhi123456@sohu.com
Status Recruiting
Phase N/A
Start date August 2011
Completion date September 2012

See also
  Status Clinical Trial Phase
Recruiting NCT05544123 - The Treatment Situation of Chinese County Population With Breast Cancer
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Active, not recruiting NCT01247480 - Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer N/A
Recruiting NCT04626986 - Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor N/A
Completed NCT04805775 - Desflurane and Postoperative Sleep Quality in Patients Undergoing Elective Breast Surgery N/A
Recruiting NCT03347864 - 68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients Early Phase 1
Completed NCT03684408 - Radiofrequency Chip for Localization of Non-Palpable Breast Lesions N/A
Recruiting NCT04692818 - 3D Ultrasound Breast Imaging N/A
Not yet recruiting NCT04825444 - Clinical Study of Vascular Imaging Evaluation of Computed Tomography Photoacoustic Breast Imaging System
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT02470819 - Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer N/A
Completed NCT00859261 - Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound N/A
Active, not recruiting NCT05169437 - Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors Phase 2
Recruiting NCT03870620 - Metastatic Breast Cancer in Austria
Completed NCT05185752 - Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery N/A
Recruiting NCT04852926 - Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.
Recruiting NCT06172270 - Sub-regional Tumor Segmentation Based on CEUS Perfusion Characteristics: Enhancing Breast Tumor Diagnosis
Recruiting NCT04948983 - The Effect of a Patient Decision Aids for Breast Cancer Screening N/A
Not yet recruiting NCT06251544 - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer Phase 1